Transition Therapeutics Inc. has acquired the development and commercialization rights to the neuropsychiatric drug candidate, ELND005, from Perrigo. ELND005 is an oral drug candidate being evaluated in three Phase II studies for agitation and aggression in Alzheimer’s disease, bipolar disorder and Down syndrome. Additionally, Perrigo will invest $15 million and acquire approximately 7% of Transition’s common shares.   Through a series of transactions, Perrigo has transferred its ELN...